35 research outputs found
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes
Get PDFC5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). However, C3-bound PNH red blood cells (RBCs), arising in almost all treated patients, may undergo extravascular hemolysis reducing clinical benefits. Despite the uniform deficiency of CD55 and of CD59, there are always two distinct populations of PNH RBCs, with (C3+) and without (C3-) C3 binding
‘Meaningful service’: Pedagogy at Israeli pre-military academies and the ethics of militarism
Get PDFA panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia
Full text linkPotential link between MHC–self-peptide presentation and hematopoiesis; the analysis of HLA-DR expression in CD34-positive cells and self-peptide presentation repertoires of MHC molecules associated with paroxysmal nocturnal hemoglobinuria
Full text linkPlasmodium falciparum malaria and invasive bacterial co-infection in young African children: the dysfunctional spleen hypothesis
Full text link
The Role of Whole-Body Magnetic Resonance Imaging (WB-MRI) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
No full textEffect of Streptomycin on Ribosome Interconversion, a Possible Basis for the Action of the Antibiotic
No full textThe role of CORM-2 as a modulator of oxidative stress and hemostatic parameters of human plasma in vitro
No full text
